摘要
B型利钠肽（BNP）和N-末端B型利钠肽原（NT-proBNP）是心力衰竭（HF）诊断和管理最常用的标志物.中间片段心房利钠肽原（MR-proANP）是研究较为深入且广泛应用的新兴标志物.研究显示,MR-proANP可作为急性HF的独立诊断指标,但诊断价值较BNP和NT-proBNP无明显优势;预后价值特别是对慢性心力衰竭的预后判断初步显示出了较BNP和NT-proBNP更好的应用前景,但在心血管事件风险评估中的应用价值仍需进一步研究证实.MR-proANP与BNP或NT-proBNP以及其他新兴标志物联合检测对HF的预后和心血管事件风险评估更有意义.
B-type natriuretic peptide （BNP） and N-terminal proBNP （NT-proBNP） have been widely used in the diagnosis and management of heart failure（HF）. In recent years, some new biomarkers emerged in different pathophysiological procedure of HF development, such as myocardial injury, myocarditis, myocardial remodeling, etc. Mid-regional proatrial natriuretic peptide （MR-proANP） , one of the most deeply researched and widely used emerging biomarkers, has been reported that it has the same value in HF diagnosis and is better in HF prognosis, compared with BNP and NT-proBNP. MR-proANP could also be an independent factor in HF diagnosis and prognosis. However, further research is still needed in risk assessment of cardiovascular event.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2014年第7期501-504,共4页
Chinese Journal of Laboratory Medicine
关键词
心力衰竭
心钠素
生物学标记
预后
Heart failure
Atrial natriuretic factor
Biological markers
Prognosis
